Weight changes differentially impact MASLD incidence, progression and outcomes based on genetic and metabolic risk profiles.
Measured against the standard of care· AASLD 2023 Practice Guidance (with October 2024 resmetirom and November 2025 semaglutide updates) / EASL 2026 holistic guidance on the steatotic liver disease trajectory (JHEP Reports 2026;8(9):101798)
Decision at stakethe weight loss targets for MASLD prevention and resolution
… For adults with overweight or obesity, sustained loss of ≥5% of body weight reduces liver fat, 7-10% improves steatohepatitis, and ≥10% improves fibrosis. In lean MASLD the target is 3-5% loss. …
From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.
Our full summary of this standard
Lifestyle change is still the foundation of MASLD care, and it is graded by goal. For adults with overweight or obesity, sustained loss of ≥5% of body weight reduces liver fat, 7-10% improves steatohepatitis, and ≥10% improves fibrosis. In lean MASLD the target is 3-5% loss. Diet should follow a Mediterranean pattern. Sugar-sweetened beverages are restricted first; fructose and other sugars, refined carbohydrates, saturated fat, ultra-processed food and red or processed meat are also cut. Low-carbohydrate diets or time-restricted eating are acceptable if they keep Mediterranean principles. Patients should do ≥150 min/week of moderate aerobic exercise plus resistance training (resistance work protects against sarcopenia and suits patients who cannot do aerobic exercise) and should cut sedentary time. Any amount of alcohol is treated as potentially hazardous: screen with AUDIT-C, and in compensated advanced chronic liver disease (cACLD) or cirrhosis advise abstinence. Drugs and surgery are added to lifestyle, never substituted for it, and each is limited by disease stage. Resmetirom is approved by the FDA and EMA (EMA in May 2025), with diet and exercise, for noncirrhotic MASH with F2-F3 fibrosis; it is not for cirrhosis. GLP-1 receptor agonists, or dual GIP/GLP-1 agonists, are the preferred class for patients with type 2 diabetes and/or obesity. Semaglutide 2.4 mg has FDA accelerated approval and AASLD November 2025 guidance support for noncirrhotic MASH F2-F3, with cirrhosis excluded first by noninvasive tests. Anti-obesity drugs are not yet recommended in cirrhosis. Pioglitazone is for selected patients, with or without diabetes, with biopsy-proven MASH (AASLD); it is not for all patients with MASLD and should be avoided in cACLD or cirrhosis. Under AASLD 2023, vitamin E 800 IU/day is limited to biopsy-proven MASH without diabetes or cirrhosis; the 2026 EASL guidance does not cover it. Bariatric or metabolic surgery should be discussed at BMI >35 kg/m2 with comorbidity, or ≥40. In compensated cirrhosis it may help carefully selected patients (MELD <12, Child-Pugh A), usually by sleeve gastrectomy, done at high-volume centres if clinically significant portal hypertension (CSPH) is present. It is contraindicated in decompensated cirrhosis. Comorbidity care is part of MASLD treatment: cardiovascular risk, under-prescribed statins (safe in compensated cirrhosis; avoid high doses when decompensated), diabetes, sleep apnea, mental health and sleep, and vaccination.